Three companies, Immucura, Immunyo and Iaso Health GmbH, are in the crosshairs of the National Agency for the Safety of Medicines and Health Products (ANSM). This Thursday, November 28, the health agency explained that it had been “alerted by our European counterparts of the promotion by (these) companies of an unauthorized anticancer treatment (…) on their websites and social networks.”
Health authorities explain that the treatments delivered by these companies have not received any marketing authorization (AMM) in Europe.
No French patient has received one of the treatments according to the ANSM
“A treatment that does not have a Marketing Authorization may present health risks and constitute a loss of opportunities for the patient who would give up validated treatments in this context,” explains the ANSM.
The health agency explained that it had taken “health police decisions (…) in particular, to suspend the illegal advertising of this therapy until it complies with the regulations relating to the drug.”
“So far, no French patient has been positively identified as having received the treatment,” notes the ANSM.
Source: BFM TV
